Frequently Asked Questions

While all women qualify to receive the treatment and no woman will be turned away, not all women qualify to participate in the actual trial, which is limited to 50 women. Preference and expedited treatment is given to women who have their own or donor embryos ready for implantation and can have implantation done at one of our clinical trial facilities in California, New York, or Chicago.

No woman will be turned away who wants to receive the treatment. Please complete the application form here, and we will find a way to help.

Again, no woman will be turned away.

You will not be able to participate in the pilot trials, but you will be able to receive the treatment used in the trials here in the U.S.

Comprehensive monitoring and analysis as described above will be included, and we will notify you when the best time to begin implantation is occurring, so that you can take action immediately. You will be provided with treatment records to share with your local reproductive health facility.

Our goal in the U.S.-based pilot trials is to expedite the original endometrial rejuvenation technique as developed by our partners in Greece to that of 3 months or less, in conjunction with the medical research and clinical team listed on this site.

We have a primary focus in studying changes in uterine and endometrial health. Hormonal changes will be a focus, though we will be focusing on the restoration of endometrial receptivity – increasing the likelihood of successful implantation – as a result of the treatment.

Currently, no clinical standard exists for the successful and ongoing tracking of endometrial and uterine health for women. Our goal is to identify, define, and develop that standard, in order to ensure that the endometrial rejuvenation treatment can be used by all women as a means of restoring and maintaining the optimal state of feminine fertility and reproductive health.

Since early 2016, Inovium researchers in Greece began to explore further applications of the initial and successful Ovarian Rejuvenation Treatment. Selecting a cohort of women with strong inflammatory reactivity of the endometrial tissue, the outermost layer of the uterus, PRP infusions were administered into the endometrium. Data has been recorded in 16 women showing 9 positive IVFs. pregnancies, and live births as a result of the treatment. Endometrial thickness has shown marked increase prior to embryo transfer.

Full information can be found here.

The cost of all labworks at any of our clinical trial facilities is included, as well as those required post-treatment in your local place of residence, as well as cytological monitoring, clinical consultations, ultrasounds, treatment, blood draws, implantation/embryo transfer treatment and planning, and pre- and post-treatment lab analysis of hormone and blood-based biomarkers of health and aging-related conditions.

Initial endometrial measurement and pipelle biopsy must be done with your current local physician or reproductive specialist prior to endometrial treatment; this cost is not included and is estimated at <$750. You or your physician must mail via FedEx overnight delivery this biopsy to our research laboratories – the cost of shipping will be included in your treatment cost.

The cost of the Endometrial Rejuvenation Treatment appears as roughly $4-$5,000, and the cost of implantation/embryo transfer (with any needed medication) as $5 – $8,000.

24/7 on-demand support from our clinical research team is also provided as a free service to all patients, in order to minimize any stress while waiting for lab reports and the optimal implantation time to commence.

While rare, any additional endometrial rejuvenation treatments needed will be provided at-cost. Some women may benefit from receiving both the Ovarian and Endometrial Rejuvenation treatments.

Flights and hotel accommodations for all trial locations can be included in the cost as requested.

We work with all insurers, though participants should not depend on this, as this is neither a traditional or locally-available treatment.

If your insurance specifically provides coverage for implantation/embryo transfer and infertility testing, then we will likely be able to cover 75% or more of your costs in the trial. However, this can only be confirmed by you, in a personal, one-on-one consultation with your insurance provider.

Through PRP (Platelet Rich Plasma) injections of the patient’s own genetic material into her ovaries. Unlike traditional PRP transfusions, no donor is needed – instead, the patient’s own genetic material is used to heal the body. The basic process involves the removal of the patient’s own blood plasma, enrichment via centrifuge, and re-injection into the endometrium.

We do not advise this, for reasons of both safety and success of the treatment. Currently, while several other clinics provide PRP-based fertility treatments, none have been able to replicate the success of our researchers, and none have presented scientific evidence or patient testimonials showcasing any success for their treatments on their websites, to the press, or at fertility conferences around the world.

Inovium researchers have, and this information has been presented clearly on our website, and featured in media as diverse as Forbes, the Guardian, Gizmodo, New Scientist, and Futurism.

Additionally, PRP transfusions are a diverse medical field – the percentage and combination of different platelet counts and the equipment used to transform the blood plasma into PRP is not standard across the medical field. For this reason, success rates are also not consistent with our results, and we cannot confirm the safety of other clinics attempting to conduct ovarian rejuvenation.

Finally, there is a diversity of different equipment used to transform blood plasma into PRP – and the vast majority of this equipment is notapproved as safe for patient use in clinical trials or clinical treatment by the FDA or other national regulatory bodies. Our equipment is approved by and confirmed to be safe for use in patients by the FDA and the European Union’s Council of Competent Authorities.

Yes – uniquely safe, according to the FDA and the EU’s Council of Competent Authorities. In the EU and US, PRP transfusions are regarded as one of the safest possible treatments, and are used in the treatment of a variety of conditions. Unlike treatments that use hormones, stem cell technology, or pharmaceuticals, blood transfusions require only limited oversight to ensure safety.

In the case of our treatments, since only the patient’s own blood is used, we have an even higher level of safety, since the patient is not receiving blood from a donor that would have to be pre-screened for potential diseases.

PRP as a whole has been extremely popular in sports medicine, where it is frequently used by athletes to increase muscular repair. We are essentially applying these same principles in our trials, to evaluate the potential for long-term treatment for menopause, infertility, and the damaging age-related conditions that affect women in menopause.

While most people only ever receive a blood transfusion in an emergency, a PRP donation can be used to facilitate healing and rejuvenation within the body at any time. This is due to the presence of natural growth factors within  blood, which are increased when a blood donation is enriched via centrifuge, and turned into PRP.

The Inovium Endometrial Rejuvenation Trials will begin in September of 2017, with a limited enrollment of 50 patients total at our three primary clinics in Carlsbad, California, New York, New York, and Peoria, Illinois.

The Endometrial Rejuvenation treatment itself is available currently for a select group of women. Please fill out our “Pre-Enrollment Interest Form” if you would like to learn more.

Our researchers and clinicians maintain a large and professional medical team from a diversity of medical disciplines and have successfully treated women for infertility for over 10 years.